All News

At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.

Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.

A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.

In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.

Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.

Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.

In a phase 2 study, azacitidine plus ruxolitinib produced a 78% objective response rate in patients with chronic phase myelofibrosis.

Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.

At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.

At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.

At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.

Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.

Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.

At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.

In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.

Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.

Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for immunotherapy before liver transplant.

Andrew Moon, MD, MPH, explained how liver function, biomarkers, and patient preferences should shape multidisciplinary treatment decisions in HCC.

Hashem B. El-Serag, MD, MPH, said HCC risk in MASLD centers on advanced fibrosis and cirrhosis, while extrahepatic cancers warrant routine screening.

More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.

Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.

Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.

The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence and the data that shaped his approach.